Clinical application
- Early-stage lung cancer auxiliary screening.
- Lung nodule risk-stratification reference indicator.
Complement CT imaging assessment with an immunological dimension.
Principle
The seven lung cancer-associated autoantibodies kit detects 7 targets at the same time:
p53, GAGE7, PGP9.5, CAGE, MAGE A1, SOX2 and GBU4-5.
This assay detects autoantibodies against lung cancer-associated antigens. The invasive or indolent tendency of tumor biological activity reflected by tumor immune response signals, thereby indicating the possibility of tumor malignant transformation.
Features
Validated biomarker: Only prospectively validated lung cancer screening biomarker
High specificity: About 90% specificity with 7 autoantibody panel
High stability: Longer half-life of antibodies than antigens ensures stable detection
Non-invasive & convenient: Only requires a blood sample
Fully automated: Chemiluminescence technology, results in about 30 minutes
